Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New remote monitoring system aims to keep blood sugar patients out of the ER

NCT ID NCT05746286

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a system that lets doctors monitor patients' blood sugar and vital signs from home after they leave the hospital. The goal was to see if this remote monitoring could prevent emergency room visits and readmissions for people with unstable blood sugar levels. 40 adults who had blood sugar problems in the hospital participated. The approach used a continuous glucose monitor and a vital signs patch to alert healthcare staff to problems early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Feb 2023

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 110 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults ≥21 years old 2. Treated for dysglycemia while in the acute (inpatient) period 3. With or without diabetes including patients with the following: * newly diagnosed T2D or T1D (LADA or other late onset) * post solid organ transplant * receiving or had received chemotherapy * COPD * Respiratory infections 4. Fit for discharge home in the opinion of the primary treating clinical team 5. Able to ambulate, or complete activities of daily living appropriate to their social care setting either on their own or with support Exclusion Criteria: 1. Acute delirium or any other psychiatric condition that will not allow the person to participate 2. Current bleeding disorder 3. Lack of appropriate sites for CGM sensor or Current Health placement (sites must be free of large scars, skin irritation, surgical wounds, dressings, burns, anasarca, heavy tattooing etc.) 4. Any skin condition that prevents the use of CGM with adhesive 5. Known current pregnancy, breast feeding, or plan to become pregnant in the next 30 days 6. Unwilling to remove study devices prior to planned MRI and/or CT scan and reapply and wear after procedure(s) has completed. 7. Persistent atrial fibrillation 8. No access to home internet, cellular service or mobile telephone 9. Unwilling to use a study provided commercially available smartphone. The smartphones will be modified so they are only capable of hosting and running the study applications required for data collection. The modified smartphones will not be able to execute standard smartphone functionality such as internet browsing, texting, or making phone calls. Bluetooth functionality will remain intact as it is required for the approved applications to collect data. 10. Any other condition that, based on Investigator's judgment, would render the patient unsuitable to take part in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dysglycemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mount Sinai School of Medicine

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.